| Kaplan Meier Estimates | ||||
---|---|---|---|---|---|
5-Year Survival Rate (%) | Â | After Propensity Score Matching | |||
 | Metformin | Metformin + SGLT2 I | P | HR (95%CI) | |
All |  | 82.09 | 90.38 | 0.002 | 0.57 (0.41–0.81) |
Subgroup a | Â | Â | Â | Â | Â |
 Men |  | 77.76 | 85.09 | 0.031 | 0.62 (0.4–0.96) |
 Women |  | 84.52 | 94.8 | < 0.01 | 0.46 (0.26–0.79) |
 White |  | 80.08 | 93.96 | < 0.001 | 0.39 (0.26–0.6) |
 Non-White |  | 83.22 | 82.58 | 0.468 | 0.7 (0.27–1.85) |
 Hispanic |  | 96.4 | 98.18 | 0.464 | 0.53 (0.1–2.94) |
 Non-Hispanic |  | 75.58 | 93.83 | < 0.001 | 0.4 (0.27–0.62) |
 Age 39–59 |  | 92.73 | 94.26 | 0.305 | 0.68 (0.32–1.43) |
 Age 60–80 |  | 82.66 | 88.62 | 0.011 | 0.58 (0.38–0.88) |
MASH b |  | 93.82 | 89.89 | 0.746 | 0.82 (0.25–2.7) |